Cystic Fibrosis Pipeline Review, H2 2019 - Analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type -

DUBLIN--()--The "Cystic Fibrosis - Pipeline Review, H2 2019" drug pipelines has been added to's offering.

This report provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 34, 18, 66 and 33 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

  1. Introduction
  2. Cystic Fibrosis - Overview
  3. Cystic Fibrosis - Therapeutics Development
  4. Cystic Fibrosis - Therapeutics Assessment
  5. Cystic Fibrosis - Companies Involved in Therapeutics Development
  6. Cystic Fibrosis - Drug Profiles
  7. Cystic Fibrosis - Dormant Projects
  8. Cystic Fibrosis - Discontinued Products
  9. Cystic Fibrosis - Product Development Milestones
  10. Appendix

Companies Mentioned

  • 4D Molecular Therapeutics Inc
  • AbbVie Inc
  • Abeona Therapeutics Inc
  • Agile Sciences Inc
  • AGILeBiotics BV
  • Alaxia SAS
  • AlgiPharma AS
  • Antabio SAS
  • Arch Biopartners Inc
  • Arcturus Therapeutics Ltd
  • Armata Pharmaceuticals Inc
  • Arrevus Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Avidin Ltd
  • BioAegis Therapeutics Inc
  • Biolytx Pharmaceuticals Corp
  • Boehringer Ingelheim International GmbH
  • Breathe Easy Therapeutics Ltd
  • Calista Therapeutics Inc
  • Calithera Biosciences Inc
  • Catabasis Pharmaceuticals Inc
  • Celtaxsys Inc
  • Chiesi Farmaceutici SpA
  • Chrysalis Pharma SAS
  • Cilian AG
  • Corbus Pharmaceuticals Inc
  • CRISPR Therapeutics AG
  • CrowdOut Therapeutics
  • Cyclacel Pharmaceuticals Inc
  • Cyclenium Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Destiny Pharma Plc
  • DiscoveryBiomed Inc
  • Druggability Technologies Holdings Ltd
  • Editas Medicine Inc
  • Eloxx Pharmaceuticals Inc
  • EmphyCorp Inc
  • EnBiotix Inc
  • Enterprise Therapeutics Ltd
  • Entrinsic Health Solutions, Inc.
  • Enzyvant Sciences Ltd
  • Errant Gene Therapeutics LLC
  • Evaxion Biotech ApS
  • Evotec SE
  • Exotect LLC
  • Feldan Therapeutics Inc
  • Galapagos NV
  • Generation Bio Corp
  • and many more...

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900